Peter Lansbury

Peter is a world expert in preclinical assay development and translational strategies for probing neurodegenerative phenotypes including Parkinson's Disease. He is currently Chief Scientific Officer of Bial Therapeutics. Previously, Peter was the CSO at Lysosomal Therapeutics and Founder at Link Medicine both which had a focus on mitochondrial life cycle/dysfunction. Peter was also a Founder of Laboratory of Drug Discovery in Neurodegeneration at Brigham & Women’s and Harvard Medical School.